Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy.

Héritier S, Emile JF, Barkaoui MA, Thomas C, Fraitag S, Boudjemaa S, Renaud F, Moreau A, Peuchmaur M, Chassagne-Clément C, Dijoud F, Rigau V, Moshous D, Lambilliotte A, Mazingue F, Kebaili K, Miron J, Jeziorski E, Plat G, Aladjidi N, Ferster A, Pacquement H, Galambrun C, Brugières L, Leverger G, Mansuy L, Paillard C, Deville A, Armari-Alla C, Lutun A, Gillibert-Yvert M, Stephan JL, Cohen-Aubart F, Haroche J, Pellier I, Millot F, Lescoeur B, Gandemer V, Bodemer C, Lacave R, Hélias-Rodzewicz Z, Taly V, Geissmann F, Donadieu J.

J Clin Oncol. 2016 Sep 1;34(25):3023-30. doi: 10.1200/JCO.2015.65.9508. Epub 2016 Jul 5.

2.

Circulating cell-free BRAFV600E as a biomarker in children with Langerhans cell histiocytosis.

Héritier S, Hélias-Rodzewicz Z, Lapillonne H, Terrones N, Garrigou S, Normand C, Barkaoui MA, Miron J, Plat G, Aladjidi N, Pagnier A, Deville A, Gillibert-Yvert M, Moshous D, Lefèvre-Utile A, Lutun A, Paillard C, Thomas C, Jeziorski E, Nizard P, Taly V, Emile JF, Donadieu J.

Br J Haematol. 2017 Aug;178(3):457-467. doi: 10.1111/bjh.14695. Epub 2017 Apr 25.

PMID:
28444728
3.

[BRAF-V600E mutation and its clinical significance in children with Langerhans cell histiocytosis].

Tang X, Guo X, Sun LY, Ai Y, Yang X, Sun JJ, Wu JR, Gao J.

Zhongguo Dang Dai Er Ke Za Zhi. 2018 Apr;20(4):290-294. Chinese.

4.

Inflammatory serum cytokines and chemokines increase associated with the disease extent in pediatric Langerhans cell histiocytosis.

Morimoto A, Oh Y, Nakamura S, Shioda Y, Hayase T, Imamura T, Kudo K, Imashuku S; Japan Langerhans cell histiocytosis Study Group.

Cytokine. 2017 Sep;97:73-79. doi: 10.1016/j.cyto.2017.05.026. Epub 2017 Jun 2.

PMID:
28582647
5.

BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups.

Berres ML, Lim KP, Peters T, Price J, Takizawa H, Salmon H, Idoyaga J, Ruzo A, Lupo PJ, Hicks MJ, Shih A, Simko SJ, Abhyankar H, Chakraborty R, Leboeuf M, Beltrão M, Lira SA, Heym KM, Bigley V, Collin M, Manz MG, McClain K, Merad M, Allen CE.

J Exp Med. 2014 Apr 7;211(4):669-83. doi: 10.1084/jem.20130977. Epub 2014 Mar 17. Erratum in: J Exp Med. 2015 Feb 9;212(2):281.

6.

BRAF V600 mutations in Langerhans cell histiocytosis with a simple and unique assay.

Tatsuno M, Shioda Y, Iwafuchi H, Yamazaki S, Iijima K, Takahashi C, Ono H, Uchida K, Okamura O, Matubayashi M, Okuyama T, Matsumoto K, Yoshioka T, Nakazawa A.

Diagn Pathol. 2016 Apr 19;11:39. doi: 10.1186/s13000-016-0489-z.

7.

Activating BRAF V600E mutation in aggressive pediatric Langerhans cell histiocytosis: demonstration by allele-specific PCR/direct sequencing and immunohistochemistry.

Méhes G, Irsai G, Bedekovics J, Beke L, Fazakas F, Rózsa T, Kiss C.

Am J Surg Pathol. 2014 Dec;38(12):1644-8. doi: 10.1097/PAS.0000000000000304.

PMID:
25118810
8.

Langerhans cell histiocytosis: A neoplastic disorder driven by Ras-ERK pathway mutations.

Tran G, Huynh TN, Paller AS.

J Am Acad Dermatol. 2018 Mar;78(3):579-590.e4. doi: 10.1016/j.jaad.2017.09.022. Epub 2017 Oct 26. Review.

PMID:
29107340
9.

The use of BRAF V600E mutation-specific immunohistochemistry in pediatric Langerhans cell histiocytosis.

Ballester LY, Cantu MD, Lim KPH, Sarabia SF, Ferguson LS, Renee Webb C, Allen CE, McClain KL, Mohila CA, Punia JN, Roy A, López-Terrada DH, John Hicks M, Fisher KE.

Hematol Oncol. 2018 Feb;36(1):307-315. doi: 10.1002/hon.2388. Epub 2017 Feb 20.

PMID:
28219109
10.

B-RAF mutant alleles associated with Langerhans cell histiocytosis, a granulomatous pediatric disease.

Satoh T, Smith A, Sarde A, Lu HC, Mian S, Trouillet C, Mufti G, Emile JF, Fraternali F, Donadieu J, Geissmann F.

PLoS One. 2012;7(4):e33891. doi: 10.1371/journal.pone.0033891. Epub 2012 Apr 10. Erratum in: PLoS One. 2012;7(6). doi:10.1371/annotation/74a67f4e-a536-4b3f-a350-9a4c1e6bebbd. Mian, Sophie [corrected to Mian, Syed].

11.

Treatment of Langerhans cell histiocytosis: role of BRAF/MAPK inhibition.

Abla O, Weitzman S.

Hematology Am Soc Hematol Educ Program. 2015;2015:565-70. doi: 10.1182/asheducation-2015.1.565.

PMID:
26637773
12.

New somatic BRAF splicing mutation in Langerhans cell histiocytosis.

Héritier S, Hélias-Rodzewicz Z, Chakraborty R, Sengal AG, Bellanné-Chantelot C, Thomas C, Moreau A, Fraitag S, Allen CE, Donadieu J, Emile JF.

Mol Cancer. 2017 Jul 6;16(1):115. doi: 10.1186/s12943-017-0690-z.

13.

BRAF V600E expression in Langerhans cell histiocytosis: clinical and immunohistochemical study on 25 pulmonary and 54 extrapulmonary cases.

Roden AC, Hu X, Kip S, Parrilla Castellar ER, Rumilla KM, Vrana JA, Vassallo R, Ryu JH, Yi ES.

Am J Surg Pathol. 2014 Apr;38(4):548-51. doi: 10.1097/PAS.0000000000000129.

PMID:
24625419
14.

BRAF and MAP2K1 mutations in Langerhans cell histiocytosis: a study of 50 cases.

Alayed K, Medeiros LJ, Patel KP, Zuo Z, Li S, Verma S, Galbincea J, Cason RC, Luthra R, Yin CC.

Hum Pathol. 2016 Jun;52:61-7. doi: 10.1016/j.humpath.2015.12.029. Epub 2016 Feb 1.

PMID:
26980021
15.

Identification of the V600D mutation in Exon 15 of the BRAF oncogene in congenital, benign langerhans cell histiocytosis.

Kansal R, Quintanilla-Martinez L, Datta V, Lopategui J, Garshfield G, Nathwani BN.

Genes Chromosomes Cancer. 2013 Jan;52(1):99-106. doi: 10.1002/gcc.22010. Epub 2012 Sep 21.

PMID:
22996177
16.

Treatment of multisystem Langerhans cell histiocytosis. Results of the DAL-HX 83 and DAL-HX 90 studies. DAL-HX Study Group.

Minkov M, Grois N, Heitger A, Pötschger U, Westermeier T, Gadner H.

Klin Padiatr. 2000 Jul-Aug;212(4):139-44.

PMID:
10994540
17.

Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis.

Chakraborty R, Burke TM, Hampton OA, Zinn DJ, Lim KP, Abhyankar H, Scull B, Kumar V, Kakkar N, Wheeler DA, Roy A, Poulikakos PI, Merad M, McClain KL, Parsons DW, Allen CE.

Blood. 2016 Nov 24;128(21):2533-2537. Epub 2016 Oct 11.

18.

High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis.

Brown NA, Furtado LV, Betz BL, Kiel MJ, Weigelin HC, Lim MS, Elenitoba-Johnson KS.

Blood. 2014 Sep 4;124(10):1655-8. doi: 10.1182/blood-2014-05-577361. Epub 2014 Jun 30.

19.

Clinicopathological features and BRAFV600E mutations in patients with isolated hypothalamic-pituitary Langerhans cell histiocytosis.

Huo Z, Lu T, Liang Z, Ping F, Shen J, Lu J, Ma W, Zhao D, Zhong D.

Diagn Pathol. 2016 Oct 19;11(1):100.

20.

Langerhans cell histiocytosis in children: from the bench to bedside for an updated therapy.

Aricò M.

Br J Haematol. 2016 Jun;173(5):663-70. doi: 10.1111/bjh.13955. Epub 2016 Feb 23. Review.

PMID:
26913480

Supplemental Content

Support Center